Abemaciclib

#Cat: NB-64-13085-5mg **Size: 5mg**
#Cat: NB-64-13085-10mg **Size: 10 mg**
#Cat: NB-64-13085-25mg **Size: 25 mg**
#Cat: NB-64-13085-50mg **Size: 50mg**
#Cat: NB-64-13085-100mg **Size: 100 mg**
#Cat: NB-64-13085-200mg **Size: 200 mg**
#Cat: NB-64-13085-500mg **Size: 500 mg**

Chemical Properties



Cas No: 1231929-97-7
Formula: $C_{27}H_{32}F_2N_8$
Molecular weight: 506.59
Appearance: no data available
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
Targets(IC50)	CDK
In vitro	**METHODS:** HNSCC cell lines OSC-19, FaDu and YD-10B were treated with Abemaciclib (0.01-10 μ M) for 72 h, and cell viability was measured by Cell Counting Kit. **RESULTS:** Abemaciclib treatment decreased the cell viability of HNSCC cells with IC50 values ranging from 0.5 μ M to 0.7 μ M. [1] METHODS: AML cells MV4-11 were treated with Abemaciclib (0.04-5 μ M) for 24 h. The cell cycle was detected using Flow Cytometry. **RESULTS:** Abemaciclib induced G1 phase block in MV4-11 cells. The G1-phase block was maximized when the concentration was ≥320 nmol/L. The **RESULTS** showed that Abemaciclib induced G1-phase block in MV4-11 cells. [2]
In vivo	**METHODS:** To assay antitumor activity in vivo, Abemaciclib (45-90 mg/kg in 1% HEC in 20 mM phosphate buffer (pH 2.0)) was administered by gavage to BALB/c mice bearing human tongue squamous carcinoma tumors OSC-19 once daily for fourteen days. **RESULTS:** Abemaciclib significantly reduced tumor growth in OSC-19 xenografts during treatment. abemaciclib treatment decreased AKT phosphorylation but had no effect on mTOR activation. [1] **METHODS:** To assay antitumor activity in vivo, Abemaciclib (22.5-90 mg/kg in 1% HEC in 25 mmol/L PB pH2) was administered by gavage to athymic nude mice harboring melanoma A375 once a day for twenty-one days. **RESULTS:** Statistically significant tumor growth inhibition was observed with Abemaciclib at 45 or 90 mg/kg dosing regimens. abemaciclib treatment significantly reduced pS780-Rb and pS10-Histone H3 levels, suggesting that CDK4/6 inhibition resulted in cell cycle inhibition and reduced tumor cell proliferation. [3]
Kinase Assay	Cells (5×103) are plated in 96 well plates. Cells are treated the next day for 24 to 48 hours and then assessed for caspase-3 activity by Caspase-Glo-3/7 Assay, as per manufacturer's instructions and a luminescence plate reader.

Cell Research	LY2835219 is dissolved in DMSO to a 10 mM concentration.? Cells are seeded in a 96-well plate, allowed to adhere overnight, and treated with DMSO control (0.1% v/v) or the indicated compounds for 72 h. Cell viability and proliferation are determined using a Cell Counting Kit according to the manufacturer's instructions. The interaction between LY2835219 and mTOR inhibitor is determined using CompuSyn. Combination index (CI) values of 1 indicates and additive drug interaction, whereas a CI of 1 is synergistic and a CI of >1 is antagonistic.

Solubility Information

Solubility	DMSO: < 1 mg/ml,Sonication is recommended. Ethanol: 1.69 mg/mL (3.34 mM),Sonication is recommended. 10% DMSO+90% Saline: 0.1 mg/mL (0.2 mM),In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.974 mL	9.8699 mL	19.7398 mL
5 mM	0.3948 mL	1.974 mL	3.948 mL
10 mM	0.1974 mL	0.987 mL	1.974 mL
50 mM	0.0395 mL	0.1974 mL	0.3948 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible

Reference

Ni J, Kabraji S, Xie S, et al. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications. 2022, 13(1): 1-8.
Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13.
Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycledependent/ independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37.
Liu X, Hu Q, Wang W, et al. A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ER α mutants in breast cancer. Biochemical Pharmacology. 2021, 188: 114583.
Jiang L, Yu Y, Li Z, et al.BMS-265246, a Cyclin-Dependent Kinase Inhibitor, Inhibits the Infection of Herpes Simplex Virus Type 1.Viruses.2023, 15(8): 1642.
Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.
Quan C, Wu Z, Xiong J, et al.Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.Experimental Hematology & Oncology.2023, 12(1): 1-21.
Cerrato G, Liu P, Zhao L, et al.AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity.Molecular Cancer.2024, 23: 275.